PL2748166T3 - Związki pirimido-pirydazynonowe oraz ich zastosowanie - Google Patents

Związki pirimido-pirydazynonowe oraz ich zastosowanie

Info

Publication number
PL2748166T3
PL2748166T3 PL12756865T PL12756865T PL2748166T3 PL 2748166 T3 PL2748166 T3 PL 2748166T3 PL 12756865 T PL12756865 T PL 12756865T PL 12756865 T PL12756865 T PL 12756865T PL 2748166 T3 PL2748166 T3 PL 2748166T3
Authority
PL
Poland
Prior art keywords
pyrimido
pyridazinone compounds
pyridazinone
compounds
Prior art date
Application number
PL12756865T
Other languages
English (en)
Polish (pl)
Inventor
Aranapakam Venkatesan
Roger Astbury Smith
Subramanya Hosahalli
Vijay Potluri
Sunil Kumar Panigrahi
Vishnu BASETTI
Karunasree KUNTU
Original Assignee
Asana Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asana Biosciences Llc filed Critical Asana Biosciences Llc
Publication of PL2748166T3 publication Critical patent/PL2748166T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL12756865T 2011-08-23 2012-08-23 Związki pirimido-pirydazynonowe oraz ich zastosowanie PL2748166T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161526525P 2011-08-23 2011-08-23
PCT/US2012/051980 WO2013028818A1 (fr) 2011-08-23 2012-08-23 Composés de pyrimido-pyridazinone et leurs procédés d'utilisation
EP12756865.7A EP2748166B1 (fr) 2011-08-23 2012-08-23 Composés de pyrimido-pyridazinone et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
PL2748166T3 true PL2748166T3 (pl) 2019-05-31

Family

ID=46829884

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12756865T PL2748166T3 (pl) 2011-08-23 2012-08-23 Związki pirimido-pirydazynonowe oraz ich zastosowanie

Country Status (13)

Country Link
US (5) US8729079B2 (fr)
EP (4) EP4327886A3 (fr)
JP (1) JP5993010B2 (fr)
CN (2) CN108707151B (fr)
BR (1) BR112014003981A2 (fr)
CA (1) CA2846187A1 (fr)
DK (2) DK3392252T3 (fr)
ES (2) ES2690971T3 (fr)
FI (1) FI3392252T3 (fr)
IL (1) IL231082A (fr)
MX (1) MX361458B (fr)
PL (1) PL2748166T3 (fr)
WO (1) WO2013028818A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2846187A1 (fr) * 2011-08-23 2013-02-28 Endo Pharmaceuticals Inc. Composes de pyrimido-pyridazinone et leurs procedes d'utilisation
AR106830A1 (es) * 2015-12-04 2018-02-21 Asana Biosciences Llc Usos de piridazinonas para tratar el cáncer
WO2018187294A1 (fr) * 2017-04-03 2018-10-11 Asana Biosciences, Llc Combinaisons de composés de pyrimido-pyridazinone, procédés, kits et formulations associées
CN117503775A (zh) * 2017-04-28 2024-02-06 自由生物有限公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
CN111961035B (zh) * 2019-05-20 2022-11-01 南京科技职业学院 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用
CN114174298B (zh) * 2019-08-14 2023-08-01 正大天晴药业集团南京顺欣制药有限公司 哒嗪酮并嘧啶类衍生物及其医药用途
CN113583026B (zh) * 2020-04-30 2024-06-14 杭州英创医药科技有限公司 一类含有稠合三环结构的化合物
WO2022002118A1 (fr) * 2020-07-01 2022-01-06 四川海思科制药有限公司 Dérivé hétérocyclique à cycles fusionnés et son utilisation médicale
AU2022421224A1 (en) * 2021-12-22 2024-06-20 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
WO2023164024A1 (fr) 2022-02-23 2023-08-31 Teva Pharmaceuticals International Gmbh Formes à l'état solide de gusacitinib
WO2023192989A2 (fr) * 2022-04-01 2023-10-05 Azkarra Therapeutics, Inc. Composés de phtalazinone utilisés en tant qu'inhibiteurs de parp7

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE756508A (fr) * 1969-09-24 1971-03-01 Takeda Chemical Industries Ltd Derives de pyrimidopyridazine
CA1004223A (en) * 1972-05-12 1977-01-25 Theodor Denzel Amino derivatives of pyrido(2,3-d)pyridazine carboxylic acids and esters
JPS4948695U (fr) 1972-07-29 1974-04-27
JPS50101387A (fr) * 1974-01-16 1975-08-11
CA1052046A (fr) 1974-01-21 1979-04-03 American Cyanamid Company 1,4-dioxane-2,5-diones a substituants dissymetriques
US5369086A (en) 1993-04-28 1994-11-29 Zeneca Limited N-benzotriazoles
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
JPH0948695A (ja) 1995-08-02 1997-02-18 Toshiba Ceramics Co Ltd シリコン単結晶の製造方法
JP2002504550A (ja) 1998-02-25 2002-02-12 ファルマシア・アンド・アップジョン・カンパニー 抗微生物剤として有用な置換アミノメチルイソオキサゾリン誘導体
NZ511116A (en) 1998-11-10 2003-08-29 Janssen Pharmaceutica Nv HIV replication inhibiting pyrimidines
JP4977940B2 (ja) * 2000-09-22 2012-07-18 エム・エス・ディー・オス・ベー・フェー 二環式ヘテロ芳香族化合物
PL366934A1 (en) 2001-04-30 2005-02-07 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
AU2003212634A1 (en) 2002-03-11 2003-09-22 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
SG176311A1 (en) 2002-07-29 2011-12-29 Rigel Pharmaceuticals Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
WO2005080377A1 (fr) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha Composé ayant une activité d'inhibition du tgf-∃ et composition pharmaceutique contenant celui-ci
RU2405778C2 (ru) 2004-09-30 2010-12-10 Тиботек Фармасьютикалз Лтд. 5-гетероциклилпиримидины, ингибирующие вич
CN101087619B (zh) 2004-12-24 2012-12-05 西芬克斯医药有限公司 治疗或预防的方法
ES2369282T3 (es) 2005-03-25 2011-11-29 Tibotec Pharmaceuticals Inhibidores heterobicíclicos de vhc.
AU2006226322B2 (en) 2005-03-25 2012-03-29 Tibotec Pharmaceuticals Ltd. Heterobicylic inhibitors of HCV
EP1874304B1 (fr) 2005-04-29 2009-07-15 Janssen Pharmaceutica N.V. Derives de benzotriazole comme antagonistes du recepteur cannabinoide
US20090182140A1 (en) * 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
US20070161670A1 (en) 2006-01-09 2007-07-12 Bristol-Myers Squibb Company Process for the preparation of substituted heterocycles
JP2009535393A (ja) 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換２−アミノ縮合複素環式化合物
GB0625196D0 (en) 2006-12-18 2007-01-24 7Tm Pharma As Modulators of cannabinoid receptor
CN103690542B (zh) * 2006-12-28 2015-11-18 Abbvie公司 聚(adp-核糖)聚合酶抑制剂
MX2009009786A (es) 2007-03-14 2009-09-24 Exelixis Inc Inhibidores de la via de hedgehog.
TW200942537A (en) * 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
RU2011116928A (ru) * 2008-09-30 2012-11-20 Астразенека Аб (Se) Гетероциклические ингибиторы jак киназы
US20100137313A1 (en) 2008-10-03 2010-06-03 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
CA2740366A1 (fr) 2008-10-21 2010-04-29 Metabolex, Inc. Agonistes de recepteur gpr120 aryl et utilisations de ceux-ci
WO2011053861A1 (fr) * 2009-10-29 2011-05-05 Genosco Inhibiteurs de kinases
WO2011079105A1 (fr) * 2009-12-23 2011-06-30 Abbott Laboratories Nouveaux composés de thiénopyrrole
US8440662B2 (en) 2010-10-31 2013-05-14 Endo Pharmaceuticals, Inc. Substituted quinazoline and pyrido-pyrimidine derivatives
CA2846187A1 (fr) * 2011-08-23 2013-02-28 Endo Pharmaceuticals Inc. Composes de pyrimido-pyridazinone et leurs procedes d'utilisation
WO2014022728A1 (fr) 2012-08-02 2014-02-06 Endo Pharmaceuticals, Inc Dérivés 5-(quinazolin-2-yl)pyrimidin-2-amines substitués utiles comme inhibiteurs de pi3k/mtor pour le traitement du cancer
AR106830A1 (es) * 2015-12-04 2018-02-21 Asana Biosciences Llc Usos de piridazinonas para tratar el cáncer
CN117503775A (zh) * 2017-04-28 2024-02-06 自由生物有限公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型

Also Published As

Publication number Publication date
EP3404029A3 (fr) 2018-12-12
IL231082A0 (en) 2014-03-31
US9382277B2 (en) 2016-07-05
CN103974955A (zh) 2014-08-06
US10183944B2 (en) 2019-01-22
US8729079B2 (en) 2014-05-20
CN108707151B (zh) 2022-06-03
DK2748166T3 (en) 2018-10-29
EP2748166B1 (fr) 2018-07-11
WO2013028818A1 (fr) 2013-02-28
US20190092779A1 (en) 2019-03-28
IL231082A (en) 2016-09-29
EP4327886A3 (fr) 2024-05-22
US20160257691A1 (en) 2016-09-08
EP3392252B1 (fr) 2023-10-04
BR112014003981A2 (pt) 2017-03-07
US10647720B2 (en) 2020-05-12
CN108707151A (zh) 2018-10-26
US20140221315A1 (en) 2014-08-07
ES2969977T3 (es) 2024-05-23
EP4327886A2 (fr) 2024-02-28
US20130053346A1 (en) 2013-02-28
JP5993010B2 (ja) 2016-09-14
EP2748166A1 (fr) 2014-07-02
WO2013028818A8 (fr) 2013-09-19
US20200190095A1 (en) 2020-06-18
FI3392252T3 (fi) 2024-01-08
JP2014524475A (ja) 2014-09-22
ES2690971T3 (es) 2018-11-23
DK3392252T3 (da) 2024-01-08
MX2014002112A (es) 2014-09-25
EP3404029A2 (fr) 2018-11-21
EP3392252A1 (fr) 2018-10-24
MX361458B (es) 2018-12-06
CA2846187A1 (fr) 2013-02-28
CN103974955B (zh) 2018-06-19

Similar Documents

Publication Publication Date Title
HUS2100012I1 (hu) 4-Imidazopiridazin-1-il-benzamidok és 4-imidazotriazin-1-il-benzamidok mint BTK-gátlók
EP2736330A4 (fr) Composés et méthodes
EP2739144A4 (fr) Composés et ses utilisations thérapeutiques
EP2747560A4 (fr) Composés et méthodes
EP2736332A4 (fr) Composés et méthodes
GB201111705D0 (en) Compounds and their use
EP2736329A4 (fr) Composés et méthodes
IL229844B (en) Anti-psgl-1 antibodies and their use
HK1191034A1 (en) N-carboxyalkyl-auristatins and use thereof n-
IL231082A0 (en) Pyrimido-pyridazinone compounds and their use
EP3701800C0 (fr) Utilisation
AP2013006947A0 (en) Compounds and their use
EP2575453A4 (fr) Composés oligo-benzamide et leur utilisation
GB201111630D0 (en) Novel compounds and their use
EP2697386A4 (fr) Conception et utilisation de pepducine
GB201111775D0 (en) Compounds and uses thereof
GB201114448D0 (en) Compounds and their use
EP2615094A4 (fr) Composés de sesterterpène et leur utilisation
EP2693879A4 (fr) Migrastatines et leurs utilisations
HK1198587A1 (en) Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals -2-
GB201102289D0 (en) New use
GB201104444D0 (en) Compounds and their use
GB201121726D0 (en) Compounds and uses thereof
GB201121551D0 (en) Compounds and uses thereof
GB201119436D0 (en) Use